PureTech Health plc's chief innovation and strategy officer, Eric Elenko, and president, Bharatt Chowrira, disclose details about the company's decision to develop a new schizophrenia therapy that could potentially alter the market – but can the model be repeated?
Founded by PureTech in 2009, Karuna Therapeutics, Inc. went public in 2019 and was acquired by Bristol Myers Squibb for $14bn in December 2023. KarXT (xanomeline-trospium), its lead asset,...
“We started with a complete blank sheet of paper, asking ‘What can we do to treat schizophrenia?’,” said Elenko. “At that point, there was a dearth of innovation [in schizophrenia...